1. KD. Tripathi. Drugs for Peptic ulcer and Gastroesophageal Reflux Disease. Essentials of medical pharmacology. Seventh edition. 2013. Page – 649-650.
2. John L. Wallace and Keith A. Sharkey. Pharmacotherapy of Gastric acidity, Peptic ulcer and Gastroesophageal Reflux disease. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 1313-1314.
3. Gerald G. Briggs and Roger K. Freeman. R. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 3356-2775.
4. AstraZeneca. Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on July 2010] [Accessed 24th November 2020] https://www.clinicaltrials.gov/ct2/show/NCT00401752
5. E P Woodings, G T Dixon, C Harrison, P Carey, and D A Richards. Ranitidine-a new H2-receptor antagonist. NCBI; PMC US National Library of Medicine, National Institute of Health. March 1980. [Accessed 24th November 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1420359/
6. Accord Healthcare Limited. Electronic Medicines Compendium (EMC); [Revised on August 2014] [Accessed 24th November 2020] https://www.medicines.org.uk/emc/files/pil.6039.pdf
7. Glaxo Wellcome SA, Omega Pharma International & Famar ltalia S.p.A. Electronic Medicines Compendium (EMC); [Revised on August 2019] [Accessed 24th November 2020] https://www.medicines.org.uk/emc/files/pil.6491.pdf